As TLR9 signaling may contribute to the expansion of CLL cells in vivo through stimulation of the NF-κB pro-survival pathway we are currently investigating the possibility that Pgrn enhances the effects of TLR9 agonists on CLL cells. The gene discussed is NFKB1; the disease is B-cell chronic lymphocytic leukemia.